New PET tracer could spot rare heart disease without a biopsy
NCT ID NCT05184088
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This completed Phase 3 study tested whether a radioactive tracer called [18F]Florbetaben, used in PET scans, can accurately diagnose cardiac AL amyloidosis—a condition where abnormal proteins build up in the heart. 244 adults with suspected cardiac amyloidosis received a single PET scan. The goal was to see if the scan could identify the disease as reliably as a heart biopsy or other standard tests.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
[18F]Florbetaben (a radioactive tracer used in PET scans)
What this could lead to
If successful, this imaging method could provide a non-invasive way to diagnose cardiac AL amyloidosis, potentially reducing the need for heart biopsies.
What could go wrong
This is a diagnostic study, not a treatment. The imaging may not be accurate enough to replace current diagnostic methods, and results may not apply to all types of amyloidosis.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AL AMYLOIDOSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Charite Berlin
Berlin, 13353, Germany
-
Clínica Universidad de Navarra
Pamplona, 31008, Spain
-
HOPA Hamburg
Hamburg, 22767, Germany
-
Hospital University Bellvitge
Barcelona, 08907, Spain
-
Hospital University Puerta de Hierro
Madrid, 28222, Spain
-
Royal Free Hospital
London, NW3 2PF, United Kingdom
-
St Luke's Hospital
Kansas City, Kansas, 64111, United States
-
University of Augsburg
Augsburg, 86156, Germany
-
University of Essen
Essen, 45147, Germany
-
University of Heidelberg
Heidelberg, 69120, Germany
-
University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
-
University of Pittsburgh
Pittsburgh, Pennsylvania, 15213, United States
-
University of Salamanca
Salamanca, 37007, Spain
-
University of Würzburg
Würzburg, 97080, Germany